Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 2/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9098386 | 0.98 | ALDH1A1 (0.52) | ALDH1A1TSHRENPP2KDM4EMGLL | |
| SCHEMBL29116321 | 0.83 | KMT2A (0.47) | ALDH1A1TSHRENPP2KDM4E | |
| SCHEMBL19492621 | 0.80 | LPL (0.45) | ALDH1A1ENPP2KDM4EMGLLCA4 | |
| SCHEMBL20312301 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TSHRKDM4ECA4CA1 | |
| SCHEMBL30715561 | 0.79 | ENPP2 (0.42) | ALDH1A1ENPP2KDM4EMGLLCA4 | |
| SCHEMBL28033540 | 0.79 | ALDH1A1 (0.46) | ALDH1A1TSHRENPP2KDM4ECA4 | |
| SCHEMBL4775243 | 0.79 | ENPP2 (0.42) | ALDH1A1ENPP2KDM4EMGLLCA4 | |
| SCHEMBL28716968 | 0.79 | ENPP2 (0.42) | ALDH1A1ENPP2KDM4EMGLLCA4 | |
| SCHEMBL31563611 | 0.78 | MGLL (0.57) | ALDH1A1ENPP2KDM4EMGLLCA4 | |
| SCHEMBL15553769 | 0.78 | MGLL (0.57) | ALDH1A1ENPP2KDM4EMGLLCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 746 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136800-A | Single-excitation visible and near-infrared double-region emission small molecule fluorescent probe and preparation method and application thereof | 南京工业大学 | 2025-06-13 | — | — | CN | claimed |
| CN-118813217-B | Anti-collapse agent for drilling fluid and preparation method thereof | 山东得顺源石油科技有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-118813217-A | Anti-collapse agent for drilling fluid and preparation method thereof | 山东得顺源石油科技有限公司 | 2024-10-22 | — | — | CN | claimed |
| US-12102715-B1 | ROS-responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2024-10-01 | — | — | US | claimed |
| CN-113004194-B | Circular polarization luminescent organic micro-nano crystal material and preparation method and application thereof | 中国科学院化学研究所 | 2022-12-09 | — | — | CN | claimed |
| US-11179335-B1 | ROS-responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2021-11-23 | — | — | US | claimed |
| US-10517823-B1 | ROS—responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2019-12-31 | — | — | US | claimed |
| EP-4212523-B1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-12516059-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-20250352550-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | UNIV MASARYKOVA (CZ) | 2025-11-20 | — | — | US | disclosed |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | THE UAB RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| EP-1149069-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
| US-6218406-B1 | AS ANTITUMOR AND ANTILEUKEMIC AGENTS | AVENTIS PHARMA S.A. (FR) | 2001-04-17 | — | — | US | disclosed |
| US-6124465-A | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments | RHONE-POULENC S.A. (FR) | 2000-09-26 | — | — | US | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| US-6013662-A | ANTITUMOR, ANTICARCINOGENIC AGENTS | RHONE-POULENC RORER S.A. (FR) | 2000-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352550-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | FLT3, ROS1, MAP4K2 | ALDH1A1 2094/4885TSHR 3332/4885ENPP2 1040/4885 |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ALDH1A1 2850/4885TSHR 3764/4885ENPP2 3567/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | ALDH1A1 3837/4885TSHR 3647/4885ENPP2 864/4885 |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | HNRNPR, HNRNPAB, RBM3 | ALDH1A1 3179/4885TSHR 1635/4885ENPP2 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.